Showing posts with label LY3041658. Show all posts
Showing posts with label LY3041658. Show all posts

Friday, February 3, 2017

Drugs in Clinical Pipeline: LY3041658 | Treatment of Skin Diseases | Monoclonal Antibody | Chemokine (CXC) Antagonist

LY3041658 is (expected to be a) monoclonal antibody that targets and specifically bind seven human ELR+ CXC chemokines. Such antibodies are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (IBD), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer.